EAS held in contempt by Newark, N.J. federal Judge Dickinson Debevoise Dec. 23 for violating preliminary injunction barring it from disseminating allegedly false, misleading ads for BetaLean HP. Contempt finding resulted from EAS' failure to stop making certain claims, including statements that BetaLean HP's proprietary formula enhances the thermogenic effect of the product's original ephedrine/caffeine combination. EAS has since removed the disputed claims from its Web site and, pursuant to the court's order, posted the following statement, which also must be distributed to firm's distributors, retailers: "A U.S. District Court found that this claim is not true and that the proprietary formula has been found to reduce and inhibit the overall thermogenic effect of the ephedrine and caffeine combination." Argument on Cytodyne's motion to dismiss an EAS countersuit will be Jan. 27 (1"The Tan Sheet" Dec. 9, 2002, p. 8)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
Extended-release stimulants will add a new ‘Limitation of Use’ about weight loss in children under 6 years, reflecting concerns about overuse from the Make America Healthy Again commission, a concern multiple studies did not find valid.